A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma

被引:17
作者
Zahoor, Haris [1 ]
Luketich, James D. [2 ]
Levy, Ryan M. [2 ]
Awais, Omar [2 ]
Winger, Daniel G. [3 ]
Gibson, Michael K. [4 ]
Nason, Katie S. [2 ]
机构
[1] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA
[2] Univ Pittsburgh, Dept Cardiothorac Surg, Pittsburgh, PA USA
[3] Univ Pittsburgh, Translat Sci Inst, Pittsburgh, PA USA
[4] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA
关键词
RANDOMIZED CONTROLLED-TRIALS; DISEASE-FREE SURVIVAL; PREOPERATIVE CHEMORADIATION; ENDOSCOPIC ULTRASOUND; COMPLETE RESPONSE; SURGERY; CANCER; CHEMOTHERAPY; CHEMORADIOTHERAPY; OUTCOMES;
D O I
10.1016/j.jtcvs.2014.10.044
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: Prognosis for patients with locally advanced esophagogastric adenocarcinoma (EAC) is poor with surgery alone, and adjuvant therapy after open esophagectomy is frequently not tolerated. After minimally invasive esophagectomy (MIE); however, earlier return to normal function may render patients better able to receive adjuvant therapy. We examined whether primary MIE followed by adjuvant chemotherapy influenced survival compared with propensity-matched patients treated with neoadjuvant therapy. Methods: Patients with stage II or higher EAC treated with MIE (N = 375) were identified. Using 30 pretreatment covariates, propensity for assignment to either neoadjuvant followed by MIE (n = 183; 54%) or MIE as primary therapy (n = 156; 46%) was calculated, generating 97 closely matched pairs. Hazard ratios were adjusted for age, sex, body mass index, smoking, comorbidity, and final pathologic stage. Results: In propensity-matched pairs, adjusted hazard ratio for death did not differ significantly for primary MIE compared with neoadjuvant (hazard ratio, 0.83; 95% confidence interval, 0.60-1.16). Recurrence patterns were similar between groups and 65% of patients with IIb or greater pathologic stage received adjuvant therapy. Clinical staging was inaccurate in 37 out of 105 patients (35%) who underwent primary MIE (n = 18 upstaged and n = 19 downstaged). Conclusions: Primary MIE followed by adjuvant chemotherapy guided by pathologic findings did not negatively influence survival and allowed for accurate staging compared with clinical staging. Our data suggest that primary MIE in patients with resectable EAC may be a reasonable approach, improving stage-based prognostication and potentially minimizing overtreatment in patients with early stage disease through accurate stage assignments. A randomized controlled trial testing this hypothesis is needed.
引用
收藏
页码:538 / 547
页数:10
相关论文
共 48 条
[41]   A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer [J].
Urschel, JD ;
Vasan, H ;
Blewett, CJ .
AMERICAN JOURNAL OF SURGERY, 2002, 183 (03) :274-279
[42]   A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer [J].
Urschel, JD ;
Vasan, H .
AMERICAN JOURNAL OF SURGERY, 2003, 185 (06) :538-543
[43]   A Multicenter Study of Survival After Neoadjuvant Radiotherapy/Chemotherapy and Esophagectomy for ypT0N0M0R0 Esophageal Cancer [J].
Vallboehmer, D. ;
Hoelscher, Arnulf H. ;
DeMeester, S. ;
DeMeester, T. ;
Salo, J. ;
Peters, J. ;
Lerut, T. ;
Swisher, S. G. ;
Schroeder, W. ;
Bollschweiler, E. ;
Hofstetter, W. .
ANNALS OF SURGERY, 2010, 252 (05) :744-748
[44]   Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer [J].
van Hagen, P. ;
Hulshof, M. C. C. M. ;
van Lanschot, J. J. B. ;
Steyerberg, E. W. ;
Henegouwen, M. I. van Berge ;
Wijnhoven, B. P. L. ;
Richel, D. J. ;
Nieuwenhuijzen, G. A. P. ;
Hospers, G. A. P. ;
Bonenkamp, J. J. ;
Cuesta, M. A. ;
Blaisse, R. J. B. ;
Busch, O. R. C. ;
ten Kate, F. J. W. ;
Creemers, G. -J. ;
Punt, C. J. A. ;
Plukker, J. T. M. ;
Verheul, H. M. W. ;
Bilgen, E. J. Spillenaar ;
van Dekken, H. ;
van der Sangen, M. J. C. ;
Rozema, T. ;
Biermann, K. ;
Beukema, J. C. ;
Piet, A. H. M. ;
van Rij, C. M. ;
Reinders, J. G. ;
Tilanus, H. W. ;
van der Gaast, A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (22) :2074-2084
[45]   A comparison of multimodal therapy and surgery for esophageal adenocarcinoma [J].
Walsh, TN ;
Noonan, N ;
Hollywood, D ;
Kelly, A ;
Keeling, N ;
Hennessy, TPJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (07) :462-467
[46]   Failure patterns in patients with esophageal cancer treated with definitive chemoradiation [J].
Welsh, James ;
Settle, Stephen H. ;
Amini, Arya ;
Xiao, Lianchun ;
Suzuki, Akihiro ;
Hayashi, Yuki ;
Hofstetter, Wayne ;
Komaki, Ritsuko ;
Liao, Zhongxing ;
Ajani, Jaffer A. .
CANCER, 2012, 118 (10) :2632-2640
[47]   Endoscopic Ultrasound Does Not Accurately Stage Early Adenocarcinoma or High-Grade Dysplasia of the Esophagus [J].
Young, Patrick E. ;
Gentry, Andrew B. ;
Acosta, Ruben D. ;
Greenwald, Bruce D. ;
Riddle, Mark .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (12) :1037-1041
[48]  
Zinner MJ, 2003, ANN SURG, V238, P494